KRAS and lung adenocarcinoma: We observed 7.6% of ERBB2 mutations in our LCINS, consistent with 2%-13% reported in other populations (Figure 2; Supplementary Table S5).1-4,6 In our series, only 5.9% of patients with lung adenocarcinoma had KRAS mutations, in accordance with other LCINS studies (4.4%-18%).